Cargando…

Difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis

BACKGROUND: Alterations in plasma and intestinal metabolites contribute to the pathogenesis and progression of alcohol-related liver cirrhosis (ALC). AIM: To explore the common and different metabolites in the plasma and feces of patients with ALC and evaluate their clinical implications. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yi-Fan, Hao, Yan-Xu, Ma, Lei, Zhang, Meng-Han, Niu, Xuan-Xuan, Li, Yan, Zhang, Yuan-Yuan, Liu, Ting-Ting, Han, Ming, Yuan, Xiao-Xue, Wan, Gang, Xing, Hui-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303510/
https://www.ncbi.nlm.nih.gov/pubmed/37389241
http://dx.doi.org/10.3748/wjg.v29.i22.3534
_version_ 1785065293994786816
author Xu, Yi-Fan
Hao, Yan-Xu
Ma, Lei
Zhang, Meng-Han
Niu, Xuan-Xuan
Li, Yan
Zhang, Yuan-Yuan
Liu, Ting-Ting
Han, Ming
Yuan, Xiao-Xue
Wan, Gang
Xing, Hui-Chun
author_facet Xu, Yi-Fan
Hao, Yan-Xu
Ma, Lei
Zhang, Meng-Han
Niu, Xuan-Xuan
Li, Yan
Zhang, Yuan-Yuan
Liu, Ting-Ting
Han, Ming
Yuan, Xiao-Xue
Wan, Gang
Xing, Hui-Chun
author_sort Xu, Yi-Fan
collection PubMed
description BACKGROUND: Alterations in plasma and intestinal metabolites contribute to the pathogenesis and progression of alcohol-related liver cirrhosis (ALC). AIM: To explore the common and different metabolites in the plasma and feces of patients with ALC and evaluate their clinical implications. METHODS: According to the inclusion and exclusion criteria, 27 patients with ALC and 24 healthy controls (HCs) were selected, and plasma and feces samples were collected. Liver function, blood routine, and other indicators were detected with automatic biochemical and blood routine analyzers. Liquid chromatography-mass spectrometry was used to detect the plasma and feces metabolites of the two groups and the metabolomics of plasma and feces. Also, the correlation between metabolites and clinical features was analyzed. RESULTS: More than 300 common metabolites were identified in the plasma and feces of patients with ALC. Pathway analysis showed that these metabolites are enriched in bile acid and amino acid metabolic pathways. Compared to HCs, patients with ALC had a higher level of glycocholic acid (GCA) and taurocholic acid (TCA) in plasma and a lower level of deoxycholic acid (DCA) in the feces, while L-threonine, L-phenylalanine, and L-tyrosine increased simultaneously in plasma and feces. GCA, TCA, L-methionine, L-phenylalanine, and L-tyrosine in plasma were positively correlated with total bilirubin (TBil), prothrombin time (PT), and maddrey discriminant function score (MDF) and negatively correlated with cholinesterase (CHE) and albumin (ALB). The DCA in feces was negatively correlated with TBil, MDF, and PT and positively correlated with CHE and ALB. Moreover, we established a P/S BA ratio of plasma primary bile acid (GCA and TCA) to fecal secondary bile acid (DCA), which was relevant to TBil, PT, and MDF score. CONCLUSION: The enrichment of GCA, TCA, L-phenylalanine, L-tyrosine, and L-methionine in the plasma of patients with ALC and the reduction of DCA in feces were related to the severity of ALC. These metabolites may be used as indicators to evaluate the progression of alcohol-related liver cirrhosis.
format Online
Article
Text
id pubmed-10303510
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-103035102023-06-29 Difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis Xu, Yi-Fan Hao, Yan-Xu Ma, Lei Zhang, Meng-Han Niu, Xuan-Xuan Li, Yan Zhang, Yuan-Yuan Liu, Ting-Ting Han, Ming Yuan, Xiao-Xue Wan, Gang Xing, Hui-Chun World J Gastroenterol Observational Study BACKGROUND: Alterations in plasma and intestinal metabolites contribute to the pathogenesis and progression of alcohol-related liver cirrhosis (ALC). AIM: To explore the common and different metabolites in the plasma and feces of patients with ALC and evaluate their clinical implications. METHODS: According to the inclusion and exclusion criteria, 27 patients with ALC and 24 healthy controls (HCs) were selected, and plasma and feces samples were collected. Liver function, blood routine, and other indicators were detected with automatic biochemical and blood routine analyzers. Liquid chromatography-mass spectrometry was used to detect the plasma and feces metabolites of the two groups and the metabolomics of plasma and feces. Also, the correlation between metabolites and clinical features was analyzed. RESULTS: More than 300 common metabolites were identified in the plasma and feces of patients with ALC. Pathway analysis showed that these metabolites are enriched in bile acid and amino acid metabolic pathways. Compared to HCs, patients with ALC had a higher level of glycocholic acid (GCA) and taurocholic acid (TCA) in plasma and a lower level of deoxycholic acid (DCA) in the feces, while L-threonine, L-phenylalanine, and L-tyrosine increased simultaneously in plasma and feces. GCA, TCA, L-methionine, L-phenylalanine, and L-tyrosine in plasma were positively correlated with total bilirubin (TBil), prothrombin time (PT), and maddrey discriminant function score (MDF) and negatively correlated with cholinesterase (CHE) and albumin (ALB). The DCA in feces was negatively correlated with TBil, MDF, and PT and positively correlated with CHE and ALB. Moreover, we established a P/S BA ratio of plasma primary bile acid (GCA and TCA) to fecal secondary bile acid (DCA), which was relevant to TBil, PT, and MDF score. CONCLUSION: The enrichment of GCA, TCA, L-phenylalanine, L-tyrosine, and L-methionine in the plasma of patients with ALC and the reduction of DCA in feces were related to the severity of ALC. These metabolites may be used as indicators to evaluate the progression of alcohol-related liver cirrhosis. Baishideng Publishing Group Inc 2023-06-14 2023-06-14 /pmc/articles/PMC10303510/ /pubmed/37389241 http://dx.doi.org/10.3748/wjg.v29.i22.3534 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Observational Study
Xu, Yi-Fan
Hao, Yan-Xu
Ma, Lei
Zhang, Meng-Han
Niu, Xuan-Xuan
Li, Yan
Zhang, Yuan-Yuan
Liu, Ting-Ting
Han, Ming
Yuan, Xiao-Xue
Wan, Gang
Xing, Hui-Chun
Difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis
title Difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis
title_full Difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis
title_fullStr Difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis
title_full_unstemmed Difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis
title_short Difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis
title_sort difference and clinical value of metabolites in plasma and feces of patients with alcohol-related liver cirrhosis
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303510/
https://www.ncbi.nlm.nih.gov/pubmed/37389241
http://dx.doi.org/10.3748/wjg.v29.i22.3534
work_keys_str_mv AT xuyifan differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis
AT haoyanxu differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis
AT malei differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis
AT zhangmenghan differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis
AT niuxuanxuan differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis
AT liyan differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis
AT zhangyuanyuan differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis
AT liutingting differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis
AT hanming differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis
AT yuanxiaoxue differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis
AT wangang differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis
AT xinghuichun differenceandclinicalvalueofmetabolitesinplasmaandfecesofpatientswithalcoholrelatedlivercirrhosis